Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial - Bristol-Myers Squibb
news.bms.comSubmitted by bmscom4434 in business
CheckMate -901 is the first and only Phase 3 trial with an immunotherapy-based combination